TD Cowen reaffirmed a ‘Buy’ rating on Medtronic (MDT) with a $106 price target, citing optimism about renal denervation therapy. The company’s letter to CMS aligns on RDN coverage terms, anticipating broad-based coverage in October. With half of US patients with uncontrolled hypertension being Medicare patients, Medtronic eyes significant market potential.

Medtronic, a global healthcare technology company, develops medical devices and therapies to treat various health conditions. It aims to alleviate pain, restore health, and extend life for approximately 75 million people annually. TD Cowen sees a huge opportunity for Medtronic in RDN therapy, especially with favorable Medicare reimbursement already secured.

While Medtronic shows investment potential, other AI stocks may offer greater upside with less downside risk. For a deeply undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, check out the free report on the best short-term AI stock. Focus on emerging opportunities in the tech sector for potential growth.

Read more at Yahoo Finance: TD Cowen Affirms Buy Rating on Medtronic, Inc. (MDT) on RDN Therapy Prospects